Subtopic Deep Dive
Neuropharmacology of 7-Hydroxymitragynine
Research Guide
What is Neuropharmacology of 7-Hydroxymitragynine?
Neuropharmacology of 7-Hydroxymitragynine studies the compound's high potency as a mu-opioid receptor agonist, its biased G-protein signaling, and effects on reward pathways and tolerance in kratom (Mitragyna speciosa).
7-Hydroxymitragynine, a key metabolite of mitragynine, shows 10-30 times greater affinity for mu-opioid receptors than mitragynine (Matsumoto et al., 2004; 223 citations). Research highlights its role in kratom's analgesic effects and abuse potential through oral activity and reward mediation (Kruegel et al., 2019; 195 citations). Over 10 papers from 2004-2020 detail its receptor interactions and neuroplasticity impacts.
Why It Matters
7-Hydroxymitragynine's potency explains kratom's opioid-like reinforcement, guiding assessments of abuse liability and addiction treatment (Kruegel et al., 2019). It informs development of safer analgesics with reduced respiratory depression via biased signaling (Kruegel et al., 2016; 296 citations). Studies support regulatory decisions on kratom as a legal high with stimulant and opioid effects (Prozialeck et al., 2012; 251 citations; Babu et al., 2008; 216 citations).
Key Research Challenges
Quantifying Biased Signaling
Distinguishing G-protein bias from beta-arrestin pathways in 7-HMG requires advanced assays like BRET or Tango (Kruegel et al., 2016). Variability in kratom strains complicates potency measurements (Takayama, 2004). No standardized models exist for human-relevant neuroplasticity (Kruegel and Grundmann, 2017).
Metabolite Contribution Assessment
Determining 7-HMG's fraction of kratom's effects versus mitragynine demands pharmacokinetic studies in vivo (Kruegel et al., 2019). Mouse antinociception data may not translate to humans (Matsumoto et al., 2004). Tolerance mechanisms remain unclarified (Prozialeck et al., 2012).
Abuse Liability Prediction
Predicting reward pathway activation and dependence needs longitudinal human data beyond self-reports (Cinosi et al., 2015). Toxicology overlaps with seizures obscure pure neuropharmacology (Warner et al., 2015). Regulatory gaps hinder controlled trials (Eastlack et al., 2020).
Essential Papers
Chemistry and Pharmacology of Analgesic Indole Alkaloids from the Rubiaceous Plant, Mitragyna speciosa
Hiromitsu Takayama · 2004 · Chemical and Pharmaceutical Bulletin · 344 citations
The leaves of a tropical plant, Mitragyna speciosa KORTH (Rubiaceae), have been traditionally used as a substitute for opium. Phytochemical studies of the constituents of the plant growing in Thail...
Synthetic and Receptor Signaling Explorations of the <i>Mitragyna</i> Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators
Andrew C. Kruegel, Madalee M. Gassaway, Abhijeet Kapoor et al. · 2016 · Journal of the American Chemical Society · 296 citations
Mu-opioid receptor agonists represent mainstays of pain management. However, the therapeutic use of these agents is associated with serious side effects, including potentially lethal respiratory de...
Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects.
Walter C. Prozialeck, Jateen K Jivan, Shridhar V. Andurkar · 2012 · PubMed · 251 citations
Kratom (Mitragyna speciosa) is a plant indigenous to Thailand and Southeast Asia. Kratom leaves produce complex stimulant and opioid-like analgesic effects. In Asia, kratom has been used to stave o...
Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa
Kenjiro Matsumoto, Syunji Horie, Hayato Ishikawa et al. · 2004 · Life Sciences · 223 citations
The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse
Andrew C. Kruegel, Oliver Grundmann · 2017 · Neuropharmacology · 219 citations
Following “the Roots” of Kratom (<i>Mitragyna speciosa</i>): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries
Eduardo Cinosi, Giovanni Martinotti, Pierluigi Simonato et al. · 2015 · BioMed Research International · 219 citations
The use of substances to enhance human abilities is a constant and cross-cultural feature in the evolution of humanity. Although much has changed over time, the availability on the Internet, often ...
Opioid receptors and legal highs:<i>Salvia divinorum</i>and Kratom
Kavita M. Babu, Christopher R. McCurdy, Edward W. Boyer · 2008 · Clinical Toxicology · 216 citations
Salvia divinorum and Mitragyna speciosa ("Kratom"), two unscheduled dietary supplements whose active agents are opioid receptor agonists, have discrete psychoactive effects that have contributed to...
Reading Guide
Foundational Papers
Start with Takayama (2004; 344 citations) for alkaloid isolation, then Matsumoto et al. (2004; 223 citations) for 7-HMG antinociception, and Prozialeck et al. (2012; 251 citations) for kratom context.
Recent Advances
Kruegel et al. (2019; 195 citations) on metabolite role; Eastlack et al. (2020; 166 citations) for clinical outlook; Kruegel and Grundmann (2017; 219 citations) on neuropharmacology.
Core Methods
Receptor binding (radioligand assays), in vivo analgesia (tail-flick test), signaling (BRET/FRET for bias), pharmacokinetics (LC-MS for metabolites).
How PapersFlow Helps You Research Neuropharmacology of 7-Hydroxymitragynine
Discover & Search
Research Agent uses searchPapers and citationGraph on '7-hydroxymitragynine opioid receptor' to map 344-citation Takayama (2004) as hub, revealing Matsumoto et al. (2004) and Kruegel et al. (2019) clusters; exaSearch uncovers 50+ related kratom papers; findSimilarPapers expands to biased agonists.
Analyze & Verify
Analysis Agent applies readPaperContent to Kruegel et al. (2019) for metabolite data, verifies biased signaling claims via verifyResponse (CoVe) against Prozialeck et al. (2012), and runs PythonAnalysis on dose-response curves with NumPy for EC50 stats; GRADE grading scores Matsumoto et al. (2004) antinociception evidence as high.
Synthesize & Write
Synthesis Agent detects gaps in tolerance studies across Kruegel et al. (2016) and Warner et al. (2015), flags contradictions in abuse potential; Writing Agent uses latexEditText for methods sections, latexSyncCitations for 10-paper bibliography, latexCompile for review drafts, and exportMermaid for receptor signaling diagrams.
Use Cases
"Extract dose-response data from 7-HMG papers and plot potency vs mitragynine"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Matsumoto 2004, Kruegel 2019) → runPythonAnalysis (pandas curve fitting, matplotlib EC50 plot) → researcher gets CSV of affinities and visualized bias ratios.
"Draft LaTeX review on 7-HMG neuropharmacology with citations"
Research Agent → citationGraph → Synthesis Agent → gap detection → Writing Agent → latexEditText (structure intro/results) → latexSyncCitations (10 papers) → latexCompile → researcher gets PDF manuscript with figures.
"Find code for 7-HMG receptor binding simulations"
Research Agent → paperExtractUrls (Kruegel 2016) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow → researcher gets runnable Python scripts for G-protein bias modeling.
Automated Workflows
Deep Research workflow scans 50+ kratom papers via searchPapers → citationGraph, generating structured report on 7-HMG potency with GRADE scores. DeepScan applies 7-step CoVe to verify Kruegel et al. (2019) claims against Takayama (2004). Theorizer hypothesizes tolerance mechanisms from Matsumoto et al. (2004) and Prozialeck et al. (2012) datasets.
Frequently Asked Questions
What defines neuropharmacology of 7-Hydroxymitragynine?
It examines 7-HMG's mu-opioid agonism, G-protein bias, and reward/tolerance effects as mitragynine metabolite (Kruegel et al., 2019; Matsumoto et al., 2004).
What are key methods in this subtopic?
Mouse antinociception assays, receptor binding (Ki measurements), and signaling assays like BRET for bias (Matsumoto et al., 2004; Kruegel et al., 2016).
What are foundational papers?
Takayama (2004; 344 citations) on indole alkaloids; Matsumoto et al. (2004; 223 citations) on oral analgesia; Prozialeck et al. (2012; 251 citations) on kratom pharmacology.
What open problems exist?
Human pharmacokinetics of 7-HMG, long-term neuroplasticity, and bias for safer analgesics without tolerance (Kruegel and Grundmann, 2017; Warner et al., 2015).
Research Alkaloids: synthesis and pharmacology with AI
PapersFlow provides specialized AI tools for Pharmacology, Toxicology and Pharmaceutics researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neuropharmacology of 7-Hydroxymitragynine with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Pharmacology, Toxicology and Pharmaceutics researchers